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Abstract Endothelin-1 (ET-1) is the most potent vasoactive pep- 
tide known to date. The peptide is initially synthesized as an 
inactive precursor (proET-l) which undergoes proteolysis at spe- 
cific pairs of basic amino acids to yield bigET-1. Production of 
ET-! then proceeds by cleavage of bigET-1 by the endothelin 
converting enzyme (ECE). Here, we demonstrate that the in vitro 
cleavage of proET-1 by furin, a mammalian convertase involved 
in precursor processing, produced bigET-1. Upon further process- 
ing, bigET-1 was converted to biologically active ET-1. Further- 
more, we demonstrate that the furin inhibitor, decanoyI-Arg-Val- 
Lys-Arg chloromethylketone, abolished production of ET-1 in 
endothelial cells. 
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1. Introduction 
Endothelin-1 (ETol), a 21 amino acid peptide with potent 
vasoconstricting properties, originates from a precursor 
(human) of 212 amino acids [1] called prepro-endothelin-1. 
Removal of the signal peptide in the lumen of the rough endo- 
plasmic reticulum yields a precursor of 195 amino acids, pro- 
endothelin-1 (proET-1). The primary structure of the precursor 
reveals that the immediate precursor to ET-I, a 38 amino acid 
moiety named big-endothelin-1 (bigET-1), is flanked by pairs 
of basic amino acids. We can assume that biosynthesis of ET-1 
would consist of an initial cleavage C-terminal to the paired 
basic amino acids followed by carboxy-terminal trimming of 
bigET-1-Lys-Arg, presumably by a carboxypeptidase H-like 
enzyme. Conversion of bigET-1 into the biologically active 
ET-1 is thought o occur on the membrane of target cells, via 
the endothelin converting enzyme (ECE). Recently, a strong 
candidate for the ECE, a membrane-bound neutral metallopro- 
tease, has been cloned [2]. 
Thus, the biosynthesis of endothelin is similar to other bio- 
logically active peptides which are initially synthesized usually 
as large, inactive precursor proteins. These proproteins must be 
proteolytically cleaved at specific sites in order for the peptides 
to be liberated and exert heir biological actions. In most proc- 
essing steps, cleavage occurs on the carboxyl side of pairs of 
basic amino acids, usually Lys-Arg or Arg-Arg, followed by 
removal of the basic amino acids by carboxypeptidases [3]. 
Proproteins cleaved in such a manner, include those yielding 
a diversity of peptidergic hormones, neuropeptides, growth 
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factors, receptors, plasma proteins, cell adhesion molecules, 
proteolytic enzymes and viral glycoproteins. 
To date, none of the proteases responsible for the initial 
maturation events of the endothelin precursor have been iden- 
tified. Recently however, a new family of proteolytic enzymes 
has been characterized which possess the specificity to process 
many types of precursors at pairs of basic amino acids [4-7]. 
These mammalian subtilisin-like proprotein convertases (SPCs) 
are the higher eukaryotic ounterparts o the bacteria! subtili- 
sins and to the yeast Kexin enzyme, acalcium-dependent serine 
endoprotease pecific for cleaving on the carboxyl side of pairs 
of basic amino acids [8]. Within the last five years, up to six 
members of this class of proteases have been discovered; furin 
[9], PC2 [10], PCI/PC3 [11], PACE 4 [12], PC4 [13] and PC5/ 
PC6 [14]. Each enzyme possesses its own set of unique features 
but one common thread is their demonstrated specificity for 
cleaving mostly on the C-terminal end of pairs of basic amino 
acids. 
Within this family of endoproteases, furin is the best charac- 
terized. Northern blot analysis has revealed that the fur gene 
is expressed at different levels, in a wide variety of cell lines and 
tissues [15] including endothelial cells where ET-1 is produced 
[16]. The furin enzyme is a calcium-dependent, serine protease 
predominantly localized in the trans Golgi membrane [17] but 
it has also been detected on the cell surface [18] and extracellu- 
lady [19]. Co-expression studies have described how furin can 
efficiently and correctly process a variety of proprotein precur- 
sors into the biologically active polypeptides [17,20-32]. All 
these precursors hare the motif R-X-K/R-R- (P4-P3-P2-PI 
respectively) at the processing site. In this report we show the 
results of in vitro digestions of proET-1 by purified furin as well 
as in vivo inhibition of cleavage of proET-I. Our data indicates 
that furin is an interesting candidate nzyme involved in the 
initial steps of ET-1 biosynthesis. 
2. Materials and methods 
2.1. Materials 
Chemicals and reagents were obtained from Boehringer-Mannheim, 
Fisher or Sigma. The boc-Arg-Val-Arg-Arg-AMC were from Biochem 
Immunosystems Inc. (Laval, Canada). 
2.2. Production of proendothelin-1 in Escherichia coli 
The cDNA fragment encoding proendothelin-1 was cloned in the 
SalI/BamHI digested pQE-9 plasmid (Qiagen, Chatsworth, CA, USA). 
We produced and purified proET-1 protein using the QIAexpress ys- 
tem (Qiagen) as manufacturer's in truction. Briefly, XL-1 blue (Strat- 
agene) were transformed with plasmids containing proET-1 insert and 
cultured in 2 × YT medium. Synthesis was induced by adding isopropyl 
fl-D-thiogalactopyranoside (IPTG) to a final concentration of 2 mM. 
Cells were harvested, centrifuged and lysed in 6 M guanidine-HC1, 0.1 
M Na-phosphate, 0.01 M Tris-HCl, pH 8.0. The lysate was applied to 
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Fig. 1. SDS-PAGE of bacterial lysates and proET-1 purification. Lane 1, bacterial lysate without IPTG induction; lane 2, induced with IPTG; and 
lane 3, purified proET-1. Samples were applied to a 10% SDS polyacrylamide g l and stained with Coomassie blue. 
a column of Ni-NTA resin and elution was according to manufacturer's 
instructions. 
2.3. Production and purification of soluble furin 
BSC-40 cells were infected with a vaccinia virus recombinant 
(VV:hfur713) expressing a secreted furin (hfur713t) as pre- 
viously described [26]. After an 18 h infection, protein-free media 
(MCDB 202, Gibco/BRL) was concentrated ona Centriprep-30 (Ami- 
con) cartridge. The concentrate was diluted 5-fold with 20 mM Tris- 
HC1, pH 7.4, and loaded on a Mem-Sepl000 DEAE ion exchange 
column (Millipore). A gradient of (~750 mM NaCI in 20 mM Tris-HC1, 
pH 7.6, was used to elute the hfur713t. Fractions were tested for enzy- 
matic activity using the boc-Arg-Val-Arg-Arg-AMC fluorogenic pep- 
tide as described [19], 
2.4. In vitro digestion of proendothelin-1 
In vitro digestions were performed using 3.8/~g (160 pmol) of proET- 
1. This was digested first with 50 U of furin (1 U = 1 pmol.h -j of AMC 
from boc-Arg-Val-Arg-Arg-AMC) in 20/.tl of digestion buffer (100 mM 
HEPES, pH 7.6, 1 mM CaCI:, 0.5% Triton X-100) for 1 h. The digestion 
mixture was then adjusted to pH 4.0 and 0.1~.2 Unit of chymosin (EC 
3.4,23.4, Sigma) was used for further proteolysis (30 min). Digestion 
products were tested for pressor activity on rat vas deferens and rabbit 
carotid artery. 
2.5. Gel filtration and enzyme immunoassay 
ProET-1 (1.4pg, 60 pmol) was digested with furin for 6 h and sample 
was applied to a calibrated TSK-G3000PW gel filtration column (7.5 
mm x 600 mm, TOSO) preequilibrated with 0.1% trifluoroacetate, 50% 
acetonitrile. Proteins were eluted in this buffer at a flow rate of 0.5 
ml/min and fractions were collected every 0.5 min. Fractions were dried 
and dissoved in 20 mM Na-phosphate, 400 mM NaCI, 0.2% BSA, 
2 mM EDTA, 10% skim milk (Block Ace Snow brand), pH 7.0. The 
contents of bigET-l-like immunoreactive material were measured by 
enzyme immunoassay sdescribed previously (38), using an antibody 
which recognizes the C-terminal sequence of bigET-l including proET- 
1 (unpublished results). 
2.6. Pharmacological ssays 
Smooth muscle contractility was studied in the carotid artery 
(RbCA) of male New Zealand White rabbits (1.8-2.5 kg) and vas 
deferens (RVD) of male Wistar rats (25(~350 g). RbCa and RVD were 
prepared according to published methods [36,37]. Briefly, the animals 
were killed by stunning and exsanguination. The RbCA were removed 
and mechanically denuded of their endothelium and cut into 5-6 mm 
wide rings. Two platinum self-closure wires (8 10 mm diameter) were 
inserted though each ring. The RVD were removed, dissected from 
surrounding adipose tissue and blood vessels. Segments of 15-20 mm 
of the prostatic portion were suspended between parallel platinum 
electrodes. Tissues were suspended in 10 ml baths containing oxygen- 
ated (95% O2, 5% CO2) Krebs' solution (composition i  mM: NaC1118; 
NaHCO 3 25; KC1 4.7; KH2PO4 1.2; MgSO 4 1.2; CaC12 1.2; Glucose 10) 
at 37°C with indomethacin (1/tM). Both preparations were stretched 
to a resting tension of 2 g and equilibrated for 40-60 min. The mechan- 
ical responses were measured isometrically by Grass force transducers 
(FT03C) and recorded on a multichannel Grass polygraph (Model 7D). 
Following equilibration period, RVD were electrically stimulated 
(square-wave pulses: 50 V, 0.1 ms) at a frequency of 0.1 Hz with a Grass 
stimulator (Model $8). 
2.7. Endothelial cell culture and proteolytic inhibition by decanoyl-Arg- 
Val-Lys-Arg chloromethylketone 
Bovine aortic endothelial cells were cultured as previously described 
[16]. Cells at 80% confluency were put in serum free media (Endothelial- 
SFM, Gibco) and incubated with various concentrations (0-50 pM) 
of decanoyl-Arg-Val-Lys-Arg chloromethylketone (a generous gift of 
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Fig. 2. Purification of hfur713t on a MemSep 1000 DEAE ion exchange 
column. Diluted media was loaded on the column and furin was eluted 
by NaC1 gradient (©). Enzymatic activity (e) was detected in fraction 
12-13. NaC1 concentration was measured by refractometry. 
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Fig. 3. Gel filtration and enzyme immunoassay offurin-cleaved (e) and 
uncleaved (©) proET-1. Arrows indicate fractions where proET-1 and 
bigET-1 eluted from the column. Column was calibrated with synthetic 
ET-1 (2.5 kDa), bigET-1 (4.3 kDa), lysozyme (14.3 kDa), and chymo- 
trypsinogen (25 kDa). 
Drs Herbert Angliker and Elliott Shaw, Friedrich Miescher-Institut, 
Basel) for 18 h. Conditioned media was harvested and ET-1 specific 
radioimmunoassay (Amersham) was performed as previously described 
[161. 
3. Resu l ts  
3.1. In vitro digestions of  proET-1 by furin and chymosin 
In order for us to perform in vitro digestions of proET-1, 
sufficient quantities of the precursor had to be produced. We 
used a prokaryotic expression system which facilitated purifica- 
tion of the biosynthesized proteins. Milligram amounts of 70% 
pure proET-1, having a molecular weight of 25,000 Da as deter- 
mined by SDS-PAGE, were obtained (Fig. 1). Our source of 
furin relied on a vaccinia virus recombinant expressing a solu- 
ble form of the enzyme, hfur713t, engineered to be secreted in 
media of infected BSC-40 cells. It was previously shown that 
this protein maintains all of native furin's enzymatic properties 
[26]. In order to exclude any other proteolytic activity present 
in the conditioned media, the secreted furin was purified by ion 
exchange chromatography. Following overnight incubation of 
infected cells in protein-free media (MCDB 202), concentrated 
media containing soluble furin was diluted in 20 mM Tris, pH 
7.4, and chromatographed on a DEAE anion exchange column. 
Fig. 2 illustrates that enzymatic activity, measured by release 
of fluorescence using the Boc-Arg-Val-Arg-Arg-AMC sub- 
strate, eluted in fractions 12-13. When conditioned media from 
wild-type infected cells were chromatographed under identical 
conditions, no enzymatic activity was detected using either the 
fluorogenic substrate or the proET-1 as a substrate in all elu- 
tion fractions. 
We then tested furin's capacity to cleave proET-1 in vitro. 
Following proET-1 digestion by furin, products were chroma- 
tographed on a TSK-G3000PW gel filtration column and frac- 
tions were assayed with an antiserum recognizing bigET-1 and 
proET-1. Fig. 3 shows that, under our conditions, proET-1 is 
completely converted to a bigET-l-like peptide eluting at a 
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Fig. 4. Constriction activity of proET-1 digested with furin and chymosin (sample). (A) Contraction-response of rat vas deferens. Controls (indicated 
by arrows) were (1) digestion buffer alone, (2) chymosin and furin, (3) proET-1 alone, (4) proET-1 cleaved by furin alone, (5) proET-1 cleaved by 
chymosin alone. (B) Contraction of rabbit carotid artery with (right panel) or without (left panel) the ETA selective antagonist BQ-123. Control 
reactions also showed no pressor activity on this preparation ( ot shown). 
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Fig. 5. Effect of dec-RVKR-cmk on production of ET-1 in cultured 
endothelial cells. Levels (fmol/ml) of ET-1 was measured inconditioned 
media of cells that were incubated for 18 h in the presence of varying 
concentrations of dec-RVKR-cmk. Cell viability was unchanged when 
exposed to this inhibitor (not shown). 
position corresponding to this peptide's molecular weight on 
the gel permeation column and recognized by the antibody. 
To confirm production of a bigET-l-like peptide, the diges- 
tion products of proET-1 by furin were incubated with chy- 
mosin, an aspartyl protease previously shown to efficiently 
convert bigET-1 into ET-1. We verified for the production of 
biologically active ET-1 by pharmacological assay on the rabbit 
vas deferens and the rat carotid artery. We initially subjected 
the tissues with various controls. As depicted in Fig. 4, the 
following samples failed to elicit contraction of the tissue: 
(i) digestion buffer alone, (ii) proET-1 alone, (iii) proET-1 di- 
gested with furin alone, (iv) proET-1 digested with chymosin 
alone, (v) chymosin and furin. Only when chymosin digestion 
was performed on furin-cleaved proendothelin- 1, did we obtain 
a significant pharmacological response in the rat vas deferens 
and the rabbit carotid artery preparations. We next asked 
whether this response was blocked by the ET A antagonist, BQ- 
123. Incubation of the tissue with this compound prevented 
pharmacological response and thus confirmed the specific in- 
teraction of the produced peptide with the ETA receptor in this 
preparation. 
3.2. Inhibition of ET-1 synthesis by dec-RVKR-cmk in 
endothelial cells 
We had previously detected furin mRNA in cultured endo- 
thelial cells, the major producers of ET-1. To test whether a 
chloroalkylketone could inhibit endogenous convertase activity 
in endothelial cells, the effect of dec-RVKR-cmk was analyzed. 
As depicted in Fig. 5, ET- 1 synthesis was suppressed by increas- 
ing concentrations of the compound. Levels were at approxi- 
mately 40% of mock-treated cells (no inhibitor) with 5 tiM and 
were 9% of maximum at 50/.tM. These high concentrations (50 
pM) ofdec-RVKR-cmk had no deleterious effects on these ceils 
when viability was assessed (not shown). Thus, the results sug- 
gest that this chloroalkylketone could block cleavage of proET- 
1 in endothelial cells, possibly due to inhibition of endogenous 
furin proteolytic activity. 
4. Discussion 
Within the last four years, the discovery and characterization 
of enzymes belonging to a new family of endoproteases which 
cleave on the C-terminal of pairs of basic amino acids, brought 
to light a long-standing question as to the identification of some 
of the key players involved in production of biologically active 
peptides. There are presently six distinct members within this 
family, all possessing particular features with regards to their 
specificity, sub-cellular localization and tissue distribution. 
Two sub-groups, each having 3 members, can be readily identi- 
fied on the basis of their distribution. The furin, PACE 4 and 
PC5/PC6 enzymes are more ubiquitously distributed while the 
PC2, PC1/PC3 and PC4 enzymes are localized to endocrine/ 
neuroendocrine c lls and testicular spermatids (PC4). Thus, we 
can link processing of precursors, which follow the regulated 
pathway of secretion, to the PC2, PC1/PC3 and PC4 enzymes 
while constitutively secreted proteins would be cleaved by furin, 
PACE 4 and PC5/PC6. 
For proET-1, which contains multiple paired basic residues 
constituting processing motifs, the precursor probably goes 
through the endothelial cell's constitutive secretory pathway 
and is cleaved, initially, by endoproteases which have specificity 
for Lys-Arg or Arg-Arg sites. In the human proET-1 there are 
4 of these sites along with multiple single arginines which can 
also serve as cleavage signals. 
We recently described the presence of furin mRNA in cul- 
tured bovine endothelial cells which suggested a possible role 
in cleaving the ET-1 precursor [16]. Thus we needed to assess 
furin's specificity towards this precursor. Two furin consensus 
motifs (Arg-Ser-Lys-Arg at both the N- and C-terminal) border 
the bigET-1 peptide. Furin's ability to cleave at a Arg-X-Lys/ 
Arg-Arg site within proET-1 would suggest production of 
bigET-1-Lys-Arg. Thus, processing of the N-terminal cleavage 
motif would correspond to the intact endothelin-1 N-terminal 
while the C-terminal would have to undergo carboxyterminal 
trimming prior to cleavage by the ECE. However, when exam- 
ining the amino acid sequence of proET-1, there exists multiple 
furin cleavage signals and other similar cleavage sites like Arg- 
Arg or single Arg. One of these is located at the N-terminal 
processing site of bigET-1, where there is an overlapping furin 
cleavage motif (-Arg-Leu-Arg-Arg49-Ser-Lys-Arg52-bigET-1). 
Thus, if cleavage was to occur upstream (at Arg 49) of the known 
cleavage site (Arg 52) full biological activity would not follow 
either because of the failure of the endothelin-converting en-
zyme to produce intact ET-1 or because the Ser-Lys-Arg-endo- 
thelin-1 would not interact with its receptor. Thus, furin is very 
specific with regards to its recognition of the substrate's cleav- 
age site. 
Since digestion of proET-1 by furin putatively produced 
bigET-1-Lys-Arg, we needed to artificially produce the ET-1 
peptide. This because conversion of bigET-1 into ET-1 by the 
ECE in vivo necessitates the intact C-terminal end of bigET-1 
[33]. It had been reported that the aspartyl protease chymosin 
specifically converted bigET-1 into biologically active and in- 
tact ET-1 [34]. Production of a peptide indistinguishable from 
ET-1 as measured by pharmacological assay confirmed correct 
cleavage of the precursor by furin. 
To further authenticate furin's role in proET-1 conversion 
we used the dec-RVKR-cmk in endothelial cells. Our results are 
similar to those reported for the inhibition of processing of the 
280 J.-B. Denault et al./FEBS Letters 362 (1995) 276-280 
glycoprotein gpl60 of HIV-1 [28]. It was observed that the most 
potent chloromethylketone (dec-REKR-cmk) inhibited cleav- 
age by more than 70% at concentrations of 5/tM. At the same 
concentrations we observed a 60% inhibition in the production 
of ET-1 in endothelial cells. 
Our data suggest that furin may play a role in the biosynthe- 
sis of the ET-1 peptide. Although it remains to be determined 
if other members of this family are also involved in ET-1 bio- 
synthesis, recent findings showing presence of furin and PC5/ 
PC6 convertases in endothelial cells narrows the possibilities 
that the other SPCs are involved in proET-1 processing [35]. 
Thus, although there is presently no direct physiological role 
for furin in the biosynthesis of ET-1, it is currently the strongest 
candidate. Clearly, further work will be necessary to identify 
bona fide proET-1 processing endoprotease(s) in endothelial 
cells and in other cell types where isoforms of endothelins 
(ET-1, -2 and -3) have been detected. 
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